Scribe Therapeutics IPO
Scribe Therapeutics is a biotechnology company developing next-generation CRISPR-based genetic medicines for serious diseases. The company focuses on creating improved gene editing systems and in vivo delivery technologies to expand the therapeutic potential of gene editing beyond current limitations.
Key Facts
| Industry | Biotechnology |
| Founded | 2018 |
| Headquarters | South San Francisco, CA |
| Employees | ~200 |
| Funding | Series D funding. Total raised over $420 million in venture capital across multiple rounds. IPO completed on July 24, 2026, raising $129 million through the sale of 8.6 million shares priced at $15 per share (high end of range). Now trading publicly under ticker SCTX. |
About Scribe Therapeutics
Scribe Therapeutics is a biotechnology company founded to advance the next generation of CRISPR-based genetic medicines. The company was established by prominent CRISPR pioneers and focuses on engineering improved molecular machinery for gene editing, including novel CRISPR enzymes (CASs) and delivery systems. Scribe's platform approach aims to overcome current limitations in gene editing, such as delivery challenges, off-target effects, and limited tissue accessibility.
The company operates two main platforms: CRISPR by Design (CbD), which engineers optimized CRISPR systems, and XE platform for next-generation gene editors. Scribe is developing therapies for serious diseases across multiple therapeutic areas, including genetic disorders, oncology, and other conditions where precise gene editing could provide transformative treatment options. The company's approach differentiates itself by building proprietary editing systems rather than relying solely on naturally occurring CRISPR enzymes.
Scribe Therapeutics occupies an important position in the rapidly evolving gene editing landscape, competing with both established public companies and well-funded private competitors. The company's success in developing improved gene editing tools and demonstrating clinical potential will be critical factors in its eventual path to public markets.
IPO Status
Scribe Therapeutics successfully completed its initial public offering on July 24, 2026, raising $129 million in an upsized offering. The company priced 8.6 million shares at $15 per share, the high end of its expected range, surpassing its initial target of $100-107 million. The stock began trading under the ticker symbol SCTX and opened at $25 per share, representing a 67% jump from the IPO price on its first day of trading. The strong debut reflects significant investor appetite for CRISPR therapeutics and the company's lipid-lowering genetic medicine programs. The proceeds from the IPO will fund clinical development of Scribe's CRISPR-based genetic medicines, particularly focusing on cardiovascular disease therapies. The successful public offering marks a significant milestone for the gene editing sector, described as a rare early-stage biotech IPO in the current market. Scribe's proprietary gene editing platforms for both ex vivo and in vivo therapies, combined with strategic backing from major pharmaceutical companies including Eli Lilly and Sanofi, positioned the company favorably for its market debut. Founded with ties to UC Berkeley and Nobel Prize winner Jennifer Doudna, Scribe had previously raised over $420 million in venture capital through its Series D funding round before going public.
Competitors
Frequently Asked Questions
Does Scribe Therapeutics have a stock?
No, Scribe Therapeutics has not had an IPO yet. The company remains privately held and is focused on advancing its CRISPR-based gene editing platforms and therapeutic programs. Sign up for alerts to stay informed.
When is the Scribe Therapeutics IPO date?
Scribe Therapeutics has not announced an IPO date. While the company is considered a potential IPO candidate given its funding and development stage, no official filing or timeline has been disclosed. Sign up for alerts to stay informed.
How can I buy Scribe Therapeutics stock?
You cannot currently buy Scribe Therapeutics stock as the company is privately held. If and when the company goes public, shares would become available through brokerage accounts on public exchanges. Sign up for alerts to stay informed.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts